Efficacy of calcitriol to bone resorption and PTH level: clinical study.

Study of the effect of calcitriol (Rocaltrol) to bone markers and PTH level in 146 menopausal women. The result showed a dose of calcitriol 0.75 microgram/day for one month significantly decreased the level of PTH, bone marker for resorption and NMID osteocalcin 61.55, 69.92, 60.02 per cent respectively (p=0.000). The other group which took calcitriol 0.5 microgram/day had little change to such markers. The active form of vitamin D benefits bone health by enhancing osteocalcin formation, in addition vitamin D has moderate antiresorption and suppression of PTH secretion.

Study of the level of biochemical bone markers: NMID osteocalcin and bone resorptive marker (beta CTx) in Thai women.

Study of the level of NMID osteocalcin and Beta CTx in 700 Thai women. The mean of NMID osteocalcin = 21.45 SD = 11.18 95% CI = 20.12 to 22.79 ng/ml and betacrosslap = 0.445 ng/ml SD = 0.25 with 95% CI = 0.414 to 0.478 ng/ml in women who menopaused less than 10 years ago (n=237), these values were higher than in young adult females (n=63) and menstruating women (n=123) which was statistically significant (p=0.0001). The value of both bone markers in elderly women who had menopaused more than 10 years ago and were aged more than 60 years (n=94) showed a marked increase of NMID osteocalcin, 25.63 ng/ml SD = 14.22 ng/ml but the value of betacrosslap was below the young-menopausal women, 0.394 ng/ml SD = 0.241 ng/ml 95% CI = 0.344 to 0.444 ng/ml. Menopausal women are at a high risk of osteoporosis due to high bone turnover. In our study, the NMID osteocalcin had a high correlation with betacrosslap (r=0.789 p=0.0001) while both bone markers had a weak correlation with bone mass density of radius, lumbar spine and hip by DXA. (r=0.29 p=0.0001).